Takaaki Eguchi

Takaaki Eguchi

Auto-generated profile, based on publicly available information

Takaaki Eguchi

Department of Gastroenterology and Hepatology Osaka Saiseikai Nakatsu Hospital Osaka Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
AKAkira Kurita
Akira Kurita
SYSatoru Yasukawa
Satoru Yasukawa
YZYoh Zen
Yoh Zen
KYKenichi Yoshimura
Kenichi Yoshimura
TOTakeshi Ogura
Takeshi Ogura
SYShujiro Yazumi
Shujiro Yazumi

3 July 2019 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
Atsushi MasamuneAtsushi Masamune
Atsushi Masamune
TNTatsuhide Nabeshima
Tatsuhide Nabeshima
KKKazuhiro Kikuta
Kazuhiro Kikuta
SHShin Hamada
Shin Hamada
ENEriko Nakano
Eriko Nakano
TSTooru Shimosegawa
Tooru Shimosegawa

27 January 2017 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
RJResearch Committee of Intractable Pancreatic Diseases in Japan
Research Committee of Intractable Pancreatic Diseases in Japan
Atsushi MasamuneAtsushi Masamune
Atsushi Masamune
KKKazuhiro Kikuta
Kazuhiro Kikuta
TNTatsuhide Nabeshima
Tatsuhide Nabeshima
ENEriko Nakano
Eriko Nakano
TSTooru Shimosegawa
Tooru Shimosegawa

30 June 2017 in Digestion
Verified
Journal Article
Closed access
HYHiroshi Yamashita
Hiroshi Yamashita
AKAtsushi Kanamori
Atsushi Kanamori
CKChise Kano
Chise Kano
HHHiroki Hashimura
Hiroki Hashimura
KMKei Matsumoto
Kei Matsumoto
AOAkihiko Okada
Akihiko Okada
Background/Aim: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux esophagitis (RE) have not yet been compared using multichannel intraluminal impedance-pH (MII-pH). Methods: A total of 8 patients with persistent gastric mucosal injury, despite completing an 8-week standard PPI therapy, were enrolled in the study. While they were on standard PPI therapy, the baseline values of reflux parameters, holding time ratio (HTR) of gastric pH >4, and esophageal pH <4 were obtained by using 24 h MII-pH monitoring. They were re-evaluated after discontinuation of the therapy and 4 weeks of subsequent treatment with vonoprazan 20 mg/day. Results: The patients were found to be CYP2C19 extensive metabolizers and negative for Helicobacter pylori infection. In 7 patients (87.5%), the mucosal lesions had healed completely after vonoprazan therapy. A significant increase in gastric pH >4 HTR was observed, from 26.5 to 78.0% (p = 0.029). A reduction in esophageal pH <4 HTR was also observed but it was not statistically significant. Furthermore, acid clearance time and the total number of reflux events, including acid and proximal reflux events, were significantly reduced. Conclusion: Vonoprazan may be a better therapy for the treatment of patients with PPI-refractory RE.

29 December 2016 in Digestion
Verified
Journal Article
Open access
PDF file
MTMasahiro Tsujimae
Masahiro Tsujimae
HYHiroshi Yamashita
Hiroshi Yamashita
HHHiroki Hashimura
Hiroki Hashimura
CKChise Kano
Chise Kano
KSKeiko Shimoyama
Keiko Shimoyama
AOAkihiko Okada
Akihiko Okada
Background:Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial. Objective: To determine the efficacy of VPZ for H. pylori eradication. Methods: A total of 874 patients were enrolled; 431 received esomeprazole (EPZ) and 443 received VPZ. First-line regimens contained clarithromycin (CAM) 200 mg b.i.d., amoxicillin 750 mg b.i.d., and either EPZ 20 mg b.i.d. or VPZ 20 mg b.i.d. for 7 days. Metronidazole 250 mg b.i.d. replaced CAM in the second-line regimens. The eradication of H. pylori was assessed by 13C-urea breath tests 4-8 weeks after each therapy. Results: The overall first-line eradication rate was 79.9% (341/427) with EPZ vs. 86.3% (377/439) with VPZ (p = 0.019). The second-line eradication rate was 83.3% (45/51) with EPZ vs. 91.1% (41/45) with VPZ (p = 0.900). Conclusion: VPZ was significantly more effective than EPZ for first-line treatment. However, for second-line treatment, there was no significant difference between EPZ and VPZ.

1 January 2013 in Digestion
Verified
Journal Article
Open access
PDF file
HYHiroshi Yamashita
Hiroshi Yamashita
KAKiyoshi Ashida
Kiyoshi Ashida
TFTakumi Fukuchi
Takumi Fukuchi
YNYoshiaki Nagatani
Yoshiaki Nagatani
HKHideaki Koga
Hideaki Koga
DIDai Ito
Dai Ito
Background/Aims: A new classification of achalasia using high-resolution manometry (HRM) has recently been suggested. Pneumatic dilatation (PD) is a common treatment for primary achalasia. The usefulness of the new classification and HRM for the treatment and follow-up of patients after PD is unknown. The aim of this study was to evaluate the PD effectiveness and the predictive factors of success in Japanese patients with achalasia using HRM and the new classification of achalasia. Methods: Twenty-five patients were diagnosed with primary achalasia using HRM and treated by PD in our hospital. We evaluated symptom scores and esophageal manometry 6 and 12 months after the first PD. Results: After the first PD treatment, remission occurred in 24 out of 25 (96.0%) patients at 6 months and in 19 out of 25 (76.0%) patients at 12 months. With the new classification of achalasia, the success rates were 83.3, 80.0 and 50% for types I, II and III, respectively, 12 months after PD. The median age of the successful group was significantly greater than that of the failure group (47.1 vs. 37.0 years, p <0.05). The median residual lower esophageal sphincter (LES) pressure 6 months after PD in the successful group was significantly lower than that of the failure group (9.0 vs. 15.5 mm Hg, p <0.05). Conclusion: Good predictors of PD success were old age (>40 years) and residual LES pressures less than 15 mm Hg 6 months after PD.